MX2022015475A - Proteina de fusion que comprende il-12 y anticuerpo anti-fap, y uso de la misma. - Google Patents

Proteina de fusion que comprende il-12 y anticuerpo anti-fap, y uso de la misma.

Info

Publication number
MX2022015475A
MX2022015475A MX2022015475A MX2022015475A MX2022015475A MX 2022015475 A MX2022015475 A MX 2022015475A MX 2022015475 A MX2022015475 A MX 2022015475A MX 2022015475 A MX2022015475 A MX 2022015475A MX 2022015475 A MX2022015475 A MX 2022015475A
Authority
MX
Mexico
Prior art keywords
fap
bispecific antibody
fusion protein
specifically
cancer
Prior art date
Application number
MX2022015475A
Other languages
English (en)
Inventor
Donggeon Kim
Soomin Ryu
Dahea Lee
Dongsu Kim
Jihoon Chang
Byoung Chul Lee
Original Assignee
Kanaph Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanaph Therapeutics Inc filed Critical Kanaph Therapeutics Inc
Publication of MX2022015475A publication Critical patent/MX2022015475A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21026—Prolyl oligopeptidase (3.4.21.26), i.e. proline-specific endopeptidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un anticuerpo biespecífico que comprende IL-12 o una variante de la misma y un sitio de unión al antígeno que se une específicamente a FAP. El anticuerpo biespecífico presenta un efecto anticancerígeno por IL-12. En particular, cuando el anticuerpo anti-FAP es implementado en un anticuerpo, el cáncer se puede tratar de manera efectiva dirigiendo específicamente la FAP altamente expresada en un tumor, y localizando específicamente la IL-12 en el sitio del tumor. Por lo tanto, el anticuerpo biespecífico se puede utilizar como una composición farmacéutica para el tratamiento anticancerígeno y, por lo tanto, tiene un alto potencial de aplicación industrial.
MX2022015475A 2020-08-11 2021-08-10 Proteina de fusion que comprende il-12 y anticuerpo anti-fap, y uso de la misma. MX2022015475A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200100229 2020-08-11
PCT/KR2021/010613 WO2022035201A1 (ko) 2020-08-11 2021-08-10 Il-12 및 항-fap 항체를 포함하는 융합단백질 및 이의 용도

Publications (1)

Publication Number Publication Date
MX2022015475A true MX2022015475A (es) 2023-04-03

Family

ID=80247416

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015475A MX2022015475A (es) 2020-08-11 2021-08-10 Proteina de fusion que comprende il-12 y anticuerpo anti-fap, y uso de la misma.

Country Status (12)

Country Link
US (2) US20230295258A1 (es)
EP (2) EP4198051A4 (es)
JP (1) JP2023533042A (es)
KR (2) KR20220020227A (es)
CN (2) CN116390937A (es)
AU (1) AU2021324738B2 (es)
BR (1) BR112022026577A2 (es)
CA (1) CA3191454A1 (es)
IL (1) IL300534A (es)
MX (1) MX2022015475A (es)
TW (1) TWI819352B (es)
WO (2) WO2022035201A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230162310A (ko) * 2022-05-20 2023-11-28 주식회사 카나프테라퓨틱스 Light 단백질 및 항-fap 항체를 포함하는 융합단백질 및 이의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3924445A (en) 1973-09-28 1975-12-09 Toyota Motor Co Ltd Flow rate measuring system with calibration means
WO1993005804A1 (en) 1991-09-18 1993-04-01 Sloan-Kettering Institute For Cancer Research Activated stromal fibroblast-specific antibody, f19 and methods of using the same
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US6455677B1 (en) * 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
EP2280997A2 (en) * 2008-04-18 2011-02-09 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions
WO2011112935A2 (en) * 2010-03-12 2011-09-15 The Regents Of The University Of California Antibody fusion proteins with disrupted heparin-binding activity
WO2012020006A2 (en) 2010-08-13 2012-02-16 Roche Glycart Ag Anti-fap antibodies and methods of use
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
ES2848732T3 (es) * 2012-08-07 2021-08-11 Roche Glycart Ag Inmunoterapia mejorada
GB201402006D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
US11291721B2 (en) * 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
JP2021509820A (ja) * 2017-11-17 2021-04-08 科済生物医薬（上海）有限公司Ｃａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏ．，Ｌｔｄ． 線維芽細胞活性化タンパク質αを標的とする結合ユニットとその応用
TW202112804A (zh) 2019-06-04 2021-04-01 瑞士商分子夥伴股份有限公司 多特異性蛋白質

Also Published As

Publication number Publication date
CA3191454A1 (en) 2022-02-17
KR20220020227A (ko) 2022-02-18
US20230295258A1 (en) 2023-09-21
CN116390937A (zh) 2023-07-04
JP2023533042A (ja) 2023-08-01
WO2022035200A1 (ko) 2022-02-17
EP4198050A4 (en) 2024-05-01
AU2021324738B2 (en) 2024-05-09
EP4198051A1 (en) 2023-06-21
EP4198050A1 (en) 2023-06-21
CN116323672A (zh) 2023-06-23
AU2021324738A1 (en) 2023-03-23
US20230295327A1 (en) 2023-09-21
EP4198051A4 (en) 2024-05-01
IL300534A (en) 2023-04-01
WO2022035201A1 (ko) 2022-02-17
KR20220020229A (ko) 2022-02-18
BR112022026577A2 (pt) 2023-02-23
TWI819352B (zh) 2023-10-21
TW202219068A (zh) 2022-05-16

Similar Documents

Publication Publication Date Title
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
MX2019009967A (es) Moleculas de union biespecificas que son capaces de unirse a cd137 y a antigenos tumorales, y usos de las mismas.
CR20200467A (es) Agentes anticuerpos anti-cd25
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
GEP20237466B (en) Methods of inhibiting angiogenesis in patient
EA202090956A2 (ru) Антитела к cd73 и их применения
RU2014138039A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
RU2014138040A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
WO2021227307A8 (zh) 抗cd73抗体及其用途
MX2020011914A (es) Anticuerpos anti-dll3 y usos de los mismos.
EA202090741A1 (ru) Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака
MX2024002238A (es) Anticuerpos anti-ccr8 y uso de los mismos.
EA202190102A1 (ru) Коньюгаты антител к тканевым факторам с лекарственным средством и их применение в лечении рака
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
MX2023013726A (es) Anticuerpos multiespecificos anti-cea y anti-cd137 y metodos de uso.
MX2022015475A (es) Proteina de fusion que comprende il-12 y anticuerpo anti-fap, y uso de la misma.
PH12020551451A1 (en) Anti-cd25 for tumour specific cell depletion
EA202092122A1 (ru) Антитела против tip-1 и их применения
EA202090944A1 (ru) Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его
MX2023006777A (es) Composiciones y métodos que comprenden antagonistas de proteína 2 relacionada con frizzled secretada (sfrp2).
ZA202205813B (en) Trpv1 epitopes and antibodies
MX2021009189A (es) Belantamab mafodotin en combinación con pembrolizumab para el tratamiento del cáncer.
EA202091688A1 (ru) Конъюгаты антител к тканевому фактору с лекарственными средствами и их применение при лечении рака